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Abstract
Background: Fibrinogen concentrate (FC) is increasingly used as first line therapy in bleeding trauma patients. It
remains unproven whether FC application increases post-traumatic plasma fibrinogen concentration (FIB) in injured
patients, possibly constituting a prothrombotic risk. Thus, we investigated the evolution of FIB following trauma in
patients with or without FC therapy.
Methods: At the AUVA Trauma Centre, Salzburg, we performed a retrospective study of patients admitted to the
emergency room and whose FIB levels were documented thereafter up to day 7 post-trauma. Patients were
categorized into those with (treatment group) or without (control group) FC therapy during the first 24 h after
hospital admission. A subgroup analysis was carried out to investigate the influence of the amount of FC given.
Results: The study enrolled 435 patients: treatment group, n = 242 (56 %); control group, n = 193 (44 %), with
median Injury Severity Score of 34 vs. 22 (P < 0.001) and massive transfusion rate of 18.4 % vs. 0.2 % (P < 0.001). In
the treatment group (median FC dose 6 g), FIB was lower on admission and up to day 2 compared with the
control group. In patients receiving high (≥10 g) doses of FC, FIB was lower up to day 5 as compared to controls.
At other timepoints, FIB did not differ significantly between the groups. In the treatment vs. the control group,
other coagulation parameters such as prothrombin time index and platelet count were consistently lower, while
activated partial thromboplastin time was consistently prolonged at most timepoints. Inflammatory parameters
such as C-reactive protein, interleukin-6 and procalcitonin were generally lower in controls.
Discussion: The rise of FIB levels from day 2 onwards in our study can be attributed to an upregulated fibrinogen
synthesis in the liver, occurring in both study groups as part of the acute phase response after tissue injury.
Conclusions: The treatment of severe trauma patients with FC during bleeding management in the first 24 h after
hospital admission does not lead to higher FIB levels post-trauma beyond that occurring naturally due to the acute
phase response.
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Background
Acquired fibrinogen deficiency is known to occur in
trauma [1]; plasma fibrinogen (FIB) levels on admission to
the emergency room (ER) are strongly correlated with di-
lution, shock and the severity of injury [2, 3]. In bleeding
patients, FIB reaches critically low levels earlier than any
other coagulation factors [4], and low FIB levels have been
associated with increased blood loss and/or transfusion
requirements in a number of settings, including trauma
[5, 6], cardiac surgery [7, 8] and post-partum haemorrhage
[9]. During major traumatic haemorrhage, FIB is almost al-
ways the primary coagulation factor deficiency [10] and low
FIB has been shown to be a strong independent risk factor
for death in trauma patients requiring massive transfusion
[3, 11, 12]. Early replacement of fibrinogen appears to be
beneficial in trauma patients experiencing severe bleeding
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[3, 13–16]. The recent European trauma and perioperative
bleeding guidelines recommend a FIB threshold concentra-
tion of 1.5–2.0 g/l as a trigger for replacement therapy in
bleeding patients [17, 18].
Besides using antifibrinolytics when necessary, some
trauma centres employing goal-directed haemostatic ther-
apy algorithms use fibrinogen concentrate (FC) as the pri-
mary pharmacological intervention in trauma-induced
coagulopathy [19–21]. It has been questioned whether the
use of FC may lead to large, sustained increases in FIB
levels, thus possibly constituting a prothrombotic risk [22].
However, few data exist on the time course of the
haemostatic effects of FC use in clinical practice. In aortic
surgery, it has been shown that no differences exist in the
evolution of FIB on postoperative day 2 and day 10 be-
tween patients receiving either FC or fresh frozen plasma
(FFP), or both, during surgery [23]. In trauma, there are
only few published data on the time course of FIB beyond
24 h post-injury in patients who have received FC [20, 24].
Recently it was shown in a small prospective study on 77
trauma patients receiving FC ± prothrombin complex con-
centrate (PCC) or without any coagulation factor concen-
trate therapy that FIB levels increase in a similar pattern
over 7 days [25].
In the current retrospective study, we primarily aimed
to evaluate FIB levels on seven consecutive days following
traumatic injury in a large population of patients with or
without FC therapy and furthermore analysed whether the
amount of FC given in the first 24 h influences the time
course of FIB over 7 days. Secondly, we evaluated the
corresponding time course of other coagulation, haem-
atological and inflammatory parameters.
Methods
The Ethics Committee of the federal state of Salzburg
(Ethikkommission für das Bundesland Salzburg) approved
(Protocol: 415-EP/73/197-2013) this retrospective analysis
of data from patients admitted to the ER of the AUVA
Trauma Centre, Salzburg, Austria, between January 2005
and June 2015. The need for informed consent was waived.
Severely injured patients in our institution are generally
treated with a standardised goal-directed haemostatic
therapy algorithm using thromboelastometry (ROTEM®)
[26], and are admitted to the intensive care unit (ICU)
using standardised treatment protocols for trauma pa-
tients. The main inclusion criterion for a patient’s dataset
was the recording of FIB levels in our hospital trauma
database from admission to the ER up to day 7 post-
trauma (any type, including traumatic brain injury). Other
inclusion criteria were: available documentation of Injury
Severity Score (ISS), hospital mortality, sex and age;
receipt and amount of allogeneic blood products (e.g., red
blood cells [RBC], FFP and platelet concentrates) and
coagulation factor concentrates (e.g., FC and PCC) in the
first 24 h. Patients were excluded from the study if they
did not have available fibrinogen data on day 6 or 7 post-
trauma or if they died within the first 7 days. Datasets
from patients already participating in another 7 day
follow-up study were also excluded from this study [25].
Blood samples for analysis were collected according to
in-hospital standards at the following timepoints: on
admission to the ER, and every morning thereafter up to
day 7. Citrated blood samples were centrifuged and the
following coagulation parameters were assessed: fibri-
nogen concentration (Clauss method with electro-
mechanical detection using a STA-Compact analyser
[Diagnostica Stago S.A.S., Asnières sur Seine, France];
normal range 2.0–4.5 g/l), prothrombin time index (PTI;
measured using a Sysmex XE- 2100 [Roche Diagnostics,
Mannheim, Germany]; expressed as a percentage ratio,
normal range 70–120 %), activated partial thromboplastin
time (aPTT; measured using Sysmex XE-2100; normal
range 23.7–34.9 s) and antithrombin III (AT III; normal
range 80–120 %). Haemoglobin, white blood cell count
and platelet count were determined on a Sysmex SF-3000
(Sysmex Corporation, Kobe, Japan) and base excess was
determined on a Roche OMNI® S Blood Gas Analyser
(Roche Diagnostics, Mannheim, Germany). Interleukin 6
(IL-6), procalcitonin (PCT), and C-reactive protein (CRP)
were determined either on a Cobas Integra or Cobas 6000
(both Roche Diagnostics, Mannheim, Germany).
All eligible datasets were primarily categorized into two
groups: patients who received any amount of FC during
the first 24 h after hospital admission (treatment group)
and patients who did not receive any source of fibrinogen
supplementation (control group). Secondly, for subgroup
analyses the treatment group was subdivided into three
categories according to the dose of FC administered
(1–4 g, 5–9 g and ≥10 g).
Statistical analysis
Continuous study variables were analysed for normal
distribution by the Kolmogorov-Smirnov test. Based on
the underlying distribution in the treatment and control
groups, between-group comparisons were analysed using
the Mann–Whitney U test. For between-group compari-
sons of categorical variables, Fisher’s exact test was used.
Differences between four subgroups were analysed with
ANOVA/Kruskal-Wallis and the Chi-Square test. For
the subgroup analyses based on four different FC dose
ranges (0 g, 1–4 g, 5–9 g and ≥10 g) at each timepoint,
the Newman-Keuls multiple comparison test was used.
Unless otherwise stated, data are presented as median
(interquartile range [IQR]) for continuous variables, and
as number (%) for categorical variables. For all statistical
tests, a P-value <0.05 was considered significant. Statis-
tical calculations were performed using GraphPad Prism
5 (GraphPad Software, La Jolla, CA, USA).
Schlimp et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2016) 24:29 Page 2 of 11
Results
Patient characteristics
A total of 435 patients with predominantly blunt trauma
fulfilled the inclusion criteria for this study: 242 (56 %) in
the treatment group and 193 (44 %) in the control group
(FC = 0 g). Of the 435 patients, 363 (83 %) were male.
Overall, the median (IQR) age was 45 years (28–59) and
the median ISS was 27 (20–36), with 409 (94 %) patients
classified as ISS ≥16. ISS was significantly higher in pa-
tients in the treatment group compared with the control
group (34 [24–42] vs. 22 [17–27.5]; P < 0.0001). Age was
significantly lower in the treatment vs. the control group
(42 [25–54] years vs. 50 [37–65] years; P < 0.0001). Mor-
tality was similar in both groups (17 patients in the treat-
ment group [3.9 %] vs. 12 patients [2.8 %] in the control
group; P = 0.85). The number of patients who required
massive transfusion (≥10 RBC units in 24 h) was signifi-
cantly higher in the treatment group than in the control
group (79 [18.4 %] vs. 1 [0.2 %]; P < 0.0001). Overall, pa-
tients in the treatment group received 6 (3–11) units of
RBCs vs. 0 (0–0) units in the control group in the first
24 h (P < 0.0001). During the same period a median of 6 g
(4–9) FC was administered to patients in the treatment
group only. Patient characteristics of the control group
and each FC dose subgroup are shown in Table 1.
Time course of laboratory parameters in the control and
treatment groups
The time courses of FIB, PTI, aPTT, AT-III, platelet
count, haemoglobin, WBC, CRP, IL-6 and PCT during
the first 7 days after trauma are shown in Table 2.
Plasma fibrinogen levels
At admission to the ER, median FIB levels were lower in
the treatment group compared with the control group
and remained lower both at day 1 and day 2 post-
trauma. From day 3 to day 7, median FIB levels rose
above the upper normal range of 4.5 g/l and did not differ
between the two groups.
Other coagulation tests
PTI was lower in the treatment group than in the con-
trol group at all timepoints. Compared with the control
group, aPTT was prolonged in the treatment group at
Table 1 Patient characteristics of the control group and each fibrinogen concentrate dose subgroup
Control group 1–4 g FC 5–9 g FC ≥10 g FC P-valuea
(n = 193) (n = 97) (n = 93) (n = 52)
Age, years 50 (37–65) 40 (22–56) 41 (26.5–53) 43.5 (28–53.75) <0.0001
Male, n (%) 153 (79.3) 69 (71.1) 75 (80.6) 39 (75.0) 0.3513
ISS 22 (17–27.5) 29 (25–40) 34 (23–45) 41.5 (33.25–50) <0.0001
Mortality, n (%) 12 (6.2) 4 (4.1) 5 (5.4) 8 (15.4) 0.0533
Massive transfusion, n (%) 1 (0.5) 8 (8.2) 26 (28.0) 45 (86.5) <0.0001
FC, g – 3 (2–4) 6 (6–8) 12 (10.25–15.75) <0.0001
RBC
units (total) 0 (0–0) 3 (2–6) 7 (5–10) 15 (11.35–20.75) <0.0001
n (%) 25 (13.0) 74 (76.3) 87 (93.5) 52 (100) <0.0001
unitsb 3 (2–4.5) 4.5 (3–7) 7.0 (5–10) 15.0 (11.25–20.75) <0.0001
PCC
IU (total) 0 (0–0) 0 (0–0) 300 (0–1800) 3600 (1800–5400) <0.0001
n (%) 5 (2.6) 22 (22.7) 46 (49.5) 50 (96.2) <0.0001
IUb 1800 (1200–4500) 1200 (1150–1800) 1800 (1425–2400) 3600 (1800–5425) <0.0001
Platelet concentrate
units (total) – 0 (0–0) 0 (0–0) 1 (0–2) <0.0001
n (%) – 1 (1.0) 17 (18.2) 28 (53.8) <0.0001
unitsb – 2 (2–2) 2 (1.5–2.0) 2.0 (2.0–3.75) 0.2441
FFP
units (total) – – 0 (0–0) 0 (0–0) <0.0001
n (%) – – 3 (3.2) 10 (19.2) <0.0001
unitsb – – 5 (5–8) 10 (10–13) 0.0097
FC fibrinogen concentrate, FFP fresh frozen plasma, ISS injury severity score, IU international units, PCC prothrombin complex concentrate, RBC red blood cells.
aANOVA (Kruskal Wallis) P value for all four groups; bMedian (interquartile range) in patients who received that particular product
Data presented as median (interquartile range), number (%)
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Table 2 Time course of plasma fibrinogen, PTI, aPTT, AT-III, platelet count, haemoglobin, WBC, CRP, IL-6 and PCT during 7 days after trauma in overall treatment group and
control group
ER Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Fibrinogen (g/l)
Treatment 1.58 (1.07–2.03) 2.33 (2.02–2.71) 4.15 (3.47–4.83) 5.51 (4.72–6.7) 6.12 (5.12–7.54) 6.55 (5.3–7.9) 6.8 (5.41–8.19) 6.99 (5.9–8.49)
n 242 242 238 239 231 227 224 207
Control 2.46 (2–2.98) 2.75 (2.25–3.25) 4.36 (3.77–5.32) 5.74 (4.74–6.74) 6.23 (5.07–7.64) 6.67 (5.25–7.9) 6.95 (5.56–8.24) 7 (5.59–8.45)
n 191 174 169 150 149 145 147 139
P-value <0.0001 <0.0001 0.0034 0.2122 0.9996 0.6106 0.6995 0.6602
PTI (%)
Treatment 66 (54–78.5) 60 (49–69) 60 (51–72) 73 (63–86) 82 (69–93) 84 (70–99) 87.5 (73–98) 87 (77–98)
n 241 242 238 238 231 227 224 207
Control 90 (78–101) 75 (64–85) 78 (64–87) 82 (70–94) 89 (76.5–99) 92 (79–101) 94 (84–104) 92 (81–103)
n 192 175 169 150 149 145 147 140
P-value <0.0001 <0.0001 <0.0001 <0.0001 0.0009 0.0012 <0.0001 0.0038
aPTT (s)
Treatment 30 (26.2–36.4) 39.5 (35.4–45.3) 39.7 (35.5–45.2) 38.3 (34.2–43.5) 36.1 (32–40.8) 34.3 (30.9–39.1) 33.2 (30–37.7) 32.3 (29.3–37.2)
n 237 238 234 236 231 227 224 208
Control 26.6 (24.1–28.9) 32.6 (30–36.6) 35 (31.6–38.3) 34.1 (31.5–38) 33 (29.7–36.3) 31.3 (28.9–35.5) 30.5 (28–34.4) 30 (27.4–33.3)
n 192 175 168 149 149 145 147 140
P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
AT-III (%)
Treatment 73 (61–86) 57 (46.3–66) 57 (46.8–68) 57.5 (48–68.8) 64 (53–75) 71 (60–86) 82 (64–96) 89.5 (75–103)
n 103 204 182 164 152 131 119 116
Control 88 (77–97) 74.5 (65.3–84) 75 (64–85) 76 (60.5–84) 85 (72–96.5) 90 (72.5–102.5) 98 (85–108.5) 100 (89.8–111.3)
n 115 132 99 78 73 85 82 70
P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.0010
Platelet count (×109/l)
Treatment 184 (143–230) 96 (64.8–134.3) 91.5 (64.8–117) 92 (65.5–120) 111.5 (76–144) 134 (94–174) 160 (116.8–209) 205 (158–266)
n 241 242 242 241 238 237 238 229
Control 222 (174–262) 158 (130–189.5) 141 (109–175) 143 (109–175) 160 (130–200.5) 184 (155–224.8) 209 (171.5–250) 240 (197–295)
n 193 185 185 179 178 180 173 163


















Table 2 Time course of plasma fibrinogen, PTI, aPTT, AT-III, platelet count, haemoglobin, WBC, CRP, IL-6 and PCT during 7 days after trauma in overall treatment group and
control group (Continued)
Haemoglobin (g/l)
Treatment 110 (90–127) 90 (82–102) 90 (80–98) 88 (80–97) 90 (81–98) 90 (82–98) 91 (84–99) 90 (81–97)
n 242 242 242 242 241 238 238 232
Control 132 (118–142) 100 (90–111) 93 (84–109) 92 (82–106) 93 (84–104) 94 (85–105) 95 (86–106) 94 (87–106)
n 193 187 190 184 184 185 178 166
P-value <0.0001 <0.0001 0.0004 0.0008 0.0103 0.0005 0.0013 <0.0001
White Blood Cell count (×109/l)
Treatment 13.1 (10–17.7) 7.1 (5.5–9.4) 8.6 (6.5–10.4) 7.9 (6.1–9.9) 7.4 (5.7–9.9) 7.9 (6.1–10.3) 9 (7.3–11.4) 10.2 (8–12.9)
n 178 203 205 203 201 201 204 202
Control 13.3 (10.8–17.3) 8.2 (6.4–9.9) 8.1 (6.7–9.9) 7.3 (6–9.6) 7.2 (5.6–9.3) 8 (6.3–9.9) 9.3 (7–11.1) 9.6 (7.3–11.7)
n 129 131 129 128 127 128 127 125
P-value 0.8283 0.0123 0.5443 0.4120 0.3542 0.9782 0.9680 0.0819
CRP (mg/l)
Treatment N/A 70 (39.5–95.5) 174 (135.5–224.5) 182 (128–236.5) 174 (104–228) 145 (88.8–213.3) 131.5 (80.5–207.3) 143 (89–211)
n 217 197 194 206 202 198 185
Control N/A 58 (34.5–88.5) 147 (97.9–204) 145 (91–221.5) 130 (82.1–237.5) 113 (75.5–195) 94 (55.5–161) 92.9 (46.2–147.5)
n 126 116 134 125 133 133 121
P-value 0.0989 0.0015 0.0006 0.0788 0.0392 0.0010 <0.0001
IL-6 (pg/ml)
Treatment 165 (86–422) 458 (209–1276) 261 (131–702) 175 (93–413) 130 (55–243) 133 (57–249) 116 (68–224) 79 (50–120)
n 96 91 82 78 80 67 74 69
Control 67 (28–144) 103 (58–284) 78 (40–240) 93 (43–258) 61 (31–122) 65 (30–134) 44 (25–82) 39 (21–77)
n 103 61 51 50 52 49 57 47
P-value <0.0001 <0.0001 <0.0001 0.0012 0.0010 0.0005 <0.0001 0.0003
PCT (ng/ml)
Treatment N/A 2.2 (0.7–6) 2 (0.7–7.8) 1.3 (0.5–6) 1 (0.1–3) 0.7 (0.4–2.3) 0.5 (0.2–2) 0.5 (0.1–1.3)
n 50 63 75 93 90 83 95
Control N/A 0.5 (0.2–1.5) 0.4 (0.1–1.8) 0.3 (0.2–1.3) 0.3 (0.2–1.3) 0.3 (0.1–0.7) 0.2 (0.1–0.5) 0.2 (0.1–0.4)
n 53 60 53 62 62 65 66
P-value <0.0001 <0.0001 0.0001 0.0607 <0.0001 <0.0001 0.0006
aPTT activated partial thromboplastin time, AT-III antithrombin III, CRP C-reactive protein, ER emergency room, IL-6 interleukin 6, N/A not available, PCT procalcitonin, PTI prothrombin time index
P < 0.05 was considered significant


















all timepoints. AT-III was at all timepoints lower in the
treatment group in contrast to the control group.
Haematological and inflammatory parameters
At all timepoints, platelet counts were lower in the treat-
ment group compared with the control group. On ad-
mission to the ER, haemoglobin levels were ~17 % lower
in the treatment group than in the control group.
Throughout all following days post-trauma, levels fell to
a stable plateau phase in both groups with slightly lower
values in the treatment group at all timepoints.
WBC was above normal (>10 × 109/l) on admission
but normal throughout the following days without relevant
differences between groups.
CRP, IL-6 and PCT were generally higher in the treat-
ment group at most timepoints. CRP and PCT values
were not available on admission. There was a ~2.5-fold
increase in CRP levels between day 1 and day 2 followed
by a steady increase in levels that peaked at day 3 in the
treatment group and day 2 in the control group. Levels
then declined up to day 7, but were still ~2-fold higher
than the levels recorded on day 1. IL-6 and PCT peak
values were seen on day 1 in both groups.
Subgroup analyses
The time courses of FIB, as well as PTI, aPTT, AT-III,
platelet count, haemoglobin, CRP and IL-6 during the
first 7 days after trauma, categorized according to the
dose of FC administered, are shown in Figs. 1, 2 and 3,
respectively.
Plasma fibrinogen levels of subgroups
At admission to the ER and on day 1, FIB levels were
lower in each of the three FC subgroups (1–4 g, 5–9 g
and ≥10 g FC) compared with the control group (Fig. 1).
Thereafter, FIB levels remained lower only in the ≥10 g
FC subgroup up to day 5 compared with the control
group. At no timepoint was there a significant difference
between the 1–4 g and 5–9 g FC subgroups. At admis-
sion and from day 2 up to day 5 the subgroups receiving
1–4 g and 5–9 g FC were generally showing higher FIB
levels than the ≥10 g FC subgroup
Standard coagulation tests of subgroups
PTI was lower in the ≥10 g FC subgroup compared with
the control group at all timepoints (Fig. 2a). In the 1–
4 g and 5–9 g FC subgroups, PTI was lower than in the
control group on admission to the ER and up to days 4
and 2, respectively. Both the 1–4 g and 5–9 g FC sub-
groups had significantly higher PTI values compared
with the ≥10 g FC subgroup at all timepoints up to day
6, except day 1 in the 5–9 g FC subgroup. PTI values be-
tween the 1–4 g and 5–9 g FC subgroups were different
at days 3 and 4 only.
Compared with the control group, aPTT was pro-
longed in the ≥10 g FC subgroup at all timepoints
(Fig. 2b). In the 1–4 g FC subgroup, aPTT was pro-
longed compared with the control group on days 1–4
and 7. In the 5–9 g FC subgroup, aPTT was prolonged
compared with the control group at admission to the ER
and on days 1–4 and 7. The ≥10 g FC subgroup exhib-
ited prolonged aPTT compared with both the 1–4 g and
5–9 g FC subgroups at all timepoints. There were no
significant differences in aPTT values between the 1–4 g
and 5–9 g FC subgroups except on day 1.
AT-III activity was lower in the ≥10 g FC subgroup at
all timepoints (Fig. 2c). In the 1–4 g and 5–9 g FC sub-
groups, AT-III was lower compared with the control
group at all timepoints, except on day 7. The ≥10 g FC
subgroup exhibited lower AT-III compared with both
the 1–4 g and 5–9 g FC subgroups at most timepoints
except on day 7. AT-III differed between the 1–4 g and
5–9 g FC subgroups on admission to the ER and on day 1.
Haematological parameters of subgroups
At almost all timepoints, platelet counts were different
between all four groups; highest in the control group,
and lowest in the treatment group receiving ≥10 g FC
(Fig. 2d). Haemoglobin was different between all four
subgroups on admission to the ER only (control group:
132 [118–142] g/l; 1–4 g FC subgroup: 121 [1015–131] g/l;
5–9 g FC subgroup: 113 [95–129.5] g/l; ≥10 g FC subgroup:
84.5 [69–104] g/l). At all subsequent timepoints haemoglo-
bin remained stable at a plateau of ~94 g/l in the control
group and ~90 g/l in all subgroups with only slight statis-
tical differences between subgroups.
Inflammatory markers of subgroups
IL-6 levels were higher in all FC subgroups compared to
control at admission to the ER (Fig. 3a). In the ≥10 g FC
subgroup IL-6 was elevated at most timepoints com-
pared to any other subgroup.
At the majority of timepoints, between-group compari-
sons of CRP levels were similar (Fig. 3b). However, on days
6 and 7 CRP levels in the ≥10 g FC subgroup were higher
than in any other group. The control group showed lower
CRP levels on day 7 than any FC subgroup.
PCT levels were generally high in the ≥10 g FC sub-
group, but due to few available values this was mostly
insignificant (Fig. 3c).
Discussion
The most striking result of the current study is that the
evolution of FIB levels from day 3 to day 7 is similar
between patients with and without FC as haemostatic
therapy. Median FIB levels appeared to reach a plateau
at approximately 7 g/l between day 5 and day 7 post-
trauma, irrespective of initial fibrinogen supplementation.
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It is also notable in our study that post-traumatic evolu-
tion of FIB levels did not differ between the two groups
despite higher ISS, transfusion requirements, allogeneic
blood product use, or PCC administration in the treat-
ment group.
It has previously been shown that FIB levels at admis-
sion to the ER depend partly on factors such as blood
loss/dilution, signs of shock and severity of injury [2].
An analysis of trauma patients, categorized according to
whether they received FC alone, FC together with PCC,
or FC combined with PCC and FFP, showed that FIB
levels 24 h post-trauma (day 1) did not differ between
treatment groups [24]. We could recently show in a
small number of patients treated with FC and PCC, FC
alone, or no coagulation therapy, investigating thrombin
generation over the time course of 7 days that FIB levels
rose in a similar manner [25]. This finding is in line with
data from the Cryostat study which revealed that fi-
brinogen supplementation with cryoprecipitate had no
significant effect on plasma FIB levels in trauma patients
from 24 h to 28 days post-treatment [27].
In contrast to the assumption that fibrinogen supple-
mentation may potentially lead to higher FIB levels post-
trauma, our current data from 435 patients show for the
first time that irrespective of the amount of FC given,
FIB levels over the following seven days were not higher
in the FC treatment subgroups than in the control group
that did not receive FC but were even lower up to day 5
in the group receiving 10 g or more. This finding is in
agreement with data from a porcine trauma model which
demonstrated that administration of human FC did not
down-regulate endogenous fibrinogen synthesis [28].
The rise of FIB levels from day 2 onwards in our study
can be attributed to an upregulated fibrinogen synthesis
in the liver, occurring in both study groups as part of the
acute phase response after tissue injury [29]. Increased
FIB levels during the acute phase response has also been
shown in patients who received FC as targeted first-line
haemostatic therapy in aortic surgery; FC provided a
specific, significant, short-lived increase in FIB [23]. This
short-lived increase in FIB levels following FC administra-
tion has also been shown in patients undergoing cystec-
tomy or cardiopulmonary bypass [7, 43]. In both studies,
FIB levels were comparable with the control group 24 h
post-operatively. However, the time course of FIB in the
subsequent post-operative days was not determined in ei-
ther study. In the current study FIB levels appeared to
reach a plateau between day 5 and day 7 post-trauma
(with no significant differences between those days), irre-
spective of initial fibrinogen supplementation. However,
FIB levels after day 7 were not investigated; therefore, we
do not know whether (post-operative) FIB levels on day
10, as reported by Solomon et al. [23] in aortic surgery
would still be in the plateau or already in the declining
phase. It is worth noting that the aforementioned study
addresses only two timepoints with an 8-day interval in
between. Thus, it is unknown whether FIB levels at day 10
represented a continuing increase, or whether FIB levels
might have already peaked between days 2 and 10.
Patients in this study were treated according to a goal-
directed algorithm [26] based on quickly available ROTEM
parameters, such as FIBTEM clot amplitude at 10 min
(A10). On admission to the ER, median FIB levels in the
group receiving FC were below 2 g/l. Thus, FIBTEM-based
diagnosis of impaired fibrinogen contribution to clotting, as
carried out in our institution, appears to be consistent with
current internationally recommended plasma level triggers
[17, 18] in determining the need for fibrinogen supplemen-
tation in trauma patients [5]. The current subgroup analysis
shows that admission FIB levels in all patients were signifi-
cantly related to the amount of FC administered in the first
24 h. Goal-directed therapy with FC has been shown to re-
duce transfusion requirements in various clinical settings
[8, 15, 20, 30–33]. In addition, FC has been shown to
significantly diminish bleeding volume in both the clinical
setting and in animal models of trauma [8, 34–36].
There is evidence to support the effectiveness of FC in
a variety of clinical settings. However, only a few studies
have reported on the safety profile of FC [23, 30, 32, 33].
The most compelling evidence for the safety of FC has
been provided by a 27-year pharmacosurveillance program,
which reported a low incidence of thromboembolic events
[37]. A preclinical study of trauma has shown that an in-
crease in thrombin generation after FC administration is
Fig. 1 Time course of plasma fibrinogen during the first 7 days after
trauma categorized according to the dose of fibrinogen concentrate
administered. Control (white), 1–4 g FC (yellow), 5–9 g FC (orange),
≥10 g FC (red). Data shown are median, interquartile range and
range. Shaded areas represent normal laboratory value ranges (FIB:
2.0–4.5 g/l) and dots represent outliers. ER, values on admission to
the emergency room; not indicated = not significant; *P < 0.05;
**P < 0.01; ***P < 0.001; in the Newman-Keuls multiple comparisons
between all four groups
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short-lived (<6 h) [38]. A clinical study did not find an in-
crease in endogenous thrombin potential between 24 h and
7 days post-treatment with FC [25, 38]. Consistent with
these findings, the results of our study suggest that for the
trauma population, use of FC does not appear to increase
the thrombogenic status above that produced by the acute
phase response. Furthermore, polymerized fibrin, also
known as antithrombin I, can actually inhibit thrombin
generation by sequestering thrombin in the forming clot
[39], though the antithrombin effect has yet to be quanti-
fied with regard to FIB levels.
As was to be expected, haemoglobin was lower at ad-
mission in the treatment group at all timepoints and in
line with the higher transfusion rate of RBCs in the
treatment group. The time course of haemoglobin levels
over seven days post-trauma differed slightly between
control and treatment groups but mainly remained
stable at around 95 and 90 g/l, respectively. This is most
likely attributable to a balance of minor blood loss
(drains, blood sampling, re-operations) and minor trans-
fusion requirements for RBCs at the ICU, not further in-
vestigated for the purpose of this study.
Interestingly, platelet count remained lower in the
treatment group at all timepoints and was even more
significantly diminished in the subgroups receiving more
FC. This may be attributable to the severity of injury and
possible higher systemic inflammatory response [40]. This
can also be supported by the results of IL-6, CRP and
PCT, being higher in the treatment groups in our study.
Generally, CRP levels reached maximum levels by day 3
or day 4, which is in agreement with previous studies
showing that CRP levels were elevated for several days
following trauma and were not correlated with trauma
severity [41, 42].
It is of particular interest that in the treatment group
PTI was lower throughout and aPTT was prolonged at
the majority of timepoints despite the use of PCC in
about half of these patients, suggesting these patients
Fig. 2 Time course of prothrombin time index (a) activated partial thromboplastin time (b) antithrombin III (c) and platelet count (d) during the
first 7 days after trauma categorized according to the dose of fibrinogen concentrate administered. Control (white), 1–4 g FC (yellow), 5–9 g FC (orange),
≥10 g FC (red). Data shown are median, interquartile range and range. Shaded areas represent normal laboratory value ranges (PTI: 70–120 %; aPTT:
26–35 s; AT-III: 75–125 %; Plt 150–350 × 109/l) and dots represent outliers. ER, values on admission to the emergency room; not indicated = not significant;
*P< 0.05; **P< 0.01; ***P< 0.001; in the Newman-Keuls multiple comparisons between all four groups
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have a lower capacity to initiate clotting. It is important
to note that a lower PTI or prolonged aPTT may occur
despite the higher endogenous thrombin potential that
usually exists during haemodilution following trauma
and after PCC administration [44, 45]. For example,
Dunbar and Chandler showed that when all coagulation
factors and inhibitors in plasma are diluted, thrombin
generation increased and peaked when the plasma was
diluted to 40 % of normal [44].
Interestingly, one patient in the control group received
no FC therapy despite receiving massive transfusion.
This patient, who was bleeding and on pre-trauma vitamin
K antagonist therapy, needed PCC only, and maintained
sufficient functional fibrin polymerisation throughout
RBC transfusion.
Our study has several limitations. Data were collected
retrospectively from a single centre, and the baseline
characteristics between the two groups were not com-
parable. We included only those patients with FIB values
available post-trauma up to day 6 or 7. For the purpose
of this study we documented FC, PCC, platelet concen-
trate and RBC use in the first 24 h only. Therefore, the
potential effects of similar therapies after 24 h on the
study parameters could not be determined–nor could
the potential impact of other therapies at any timepoint
be excluded (e.g., tranexamic acid). The data in this study
were collected over a long time period (2005–2015),
during which changes occurred in our clinic’s standard
transfusion protocols e.g., initially, PCC was adminis-
tered more liberally but now this is only administered
after FC administration and an ongoing prolonged
EXTEM clotting time (CT). Therefore, differences in
patient management might have impacted our assessments
of patients’ haemostatic outcomes. We cannot exclude the
impact of age on the evolution of FIB levels; interestingly,
patients in the control group were significantly older than
those in the treatment group. However, in the range of ob-
served ages we consider this difference to be of minor im-
portance. It is also noteworthy that some patients in the
control group who did not present with bleeding at admis-
sion did not receive FC despite FIB levels below the current
recommended threshold levels. We did not investigate the
prothrombotic effects of FC in this study and were unable
to include any information on thromboembolic events as
patients are not routinely screened for deep vein throm-
bosis in our centre. The main problem being that markers
of thromboembolic events, such as D-dimers, are not
suitable for establishing these events in trauma patients.
However, due to the overall equal time course of FIB levels
regardless of administration of FC, this should not impact
such events per se.
Furthermore, the tendency for lower fibrinogen in the
highest FC group may be because of the need for further
operations after the initial damage control surgery in
those patients with more severe trauma. We cannot
exclude that this may have biased the results of this
group to some extent. However, it is interesting that
Fig. 3 Time course of interleukin-6 (a) C-reactive protein (b) and
procalcitonin (c) during the first 7 days after trauma categorized
according to the dose of fibrinogen concentrate administered.
Control (white), 1–4 g FC (yellow), 5–9 g FC (orange), ≥10 g FC
(red). Data shown are median, interquartile range and range. Dots
represent outliers. ER, values on admission to the emergency room;
not indicated = not significant; *P < 0.05; **P < 0.01; ***P < 0.001; in the
Newman-Keuls multiple comparisons between all four groups.
C- reactive protein and procalcitonin were not measured on
admission to the ER
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the patients who received the highest amount of FC
had the most severe injuries and presumably the most
secondary “hits” (operations), and still present with a
tendency to lower fibrinogen levels.
Conclusions
In conclusion, treatment of bleeding trauma patients
with FC during the first 24 h after hospital admission
does not affect the evolution of FIB levels from day 3 to
day 7 post-trauma compared with controls. No additional
increase in FIB was observed beyond that occurring natur-
ally due to the acute phase response after tissue injury.
We therefore suggest that administration of FC to the
trauma patient is unlikely to increase prothrombotic sta-
tus. Prospective, multicentre studies are needed to confirm
our results.
Key messages
 It has been questioned whether fibrinogen
concentrate (FC) therapy has the potential to
abnormally increase plasma fibrinogen levels thus
leading to a prothrombotic risk following trauma
 In this retrospective study, trauma patients receiving
FC therapywere compared with patients not
receiving FC
 Patients treated with FC had higher injury severity
scores and higher transfusion of allogeneic blood
products than those not receiving FC, butplasma
fibrinogen levels from day 3 to day 7 post-trauma
were similar in the two patient groups, reaching a
plateau of ~7 g/l between day 5 and day 7
 These data show that FC therapy does not lead to
higher plasma fibrinogen levels among trauma
patients
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